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Abstract: The recent biotechnology breakthrough of cell reprogramming and generation of
induced pluripotent stem cells (iPSCs), which has revolutionized the approaches to study
the mechanisms of human diseases and to test new drugs, can be exploited to generate
patient-specific models for the investigation of host–pathogen interactions and to develop
new antimicrobial and antiviral therapies. Applications of iPSC technology to the study
of viral infections in humans have included in vitro modeling of viral infections of neural,
liver, and cardiac cells; modeling of human genetic susceptibility to severe viral infectious
diseases, such as encephalitis and severe influenza; genetic engineering and genome editing
of patient-specific iPSC-derived cells to confer antiviral resistance.
Keywords: human induced pluripotent stem cells; viral infection; patient-specific
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1. Introduction
Every year, infectious diseases kill millions of people worldwide. The recent human outbreak of
Ebola virus infection in West Africa has dramatically shown the tremendous effects of a highly lethal
pathogen, against which no effective drugs or vaccines are available [1]. Other infectious diseases,
such as malaria, tuberculosis, AIDS, influenza, continue to be common causes of death especially in
low income countries and represent global health emergencies that require strengthened interventions.
At present, the only successful strategies to treat infectious diseases are based on targeting the infectious
agent, but this approach becomes ineffective with the relentless emergence of antidrug resistance.
The recent advances in the knowledge of infectious disease pathogenesis and host factors involved
in susceptibility or resistance to infectious agents have opened new perspectives for the development
of personalized therapeutic interventions based on enhancing host immune response and on conferring
a resistance state to a susceptible individual. The latter approach can be pursued by improving our
understanding of the molecular and genetic basis of human susceptibility or resistance to infectious
diseases and by developing patient-specific models for the investigation of infectious diseases and to test
new therapies.
So far, information on host factors that restrict viral infection has been achieved from large
genome-wide association studies and through the application of large-scale ectopic expression and gene
silencing screens to identify sets of genes that control viral replication in vitro or that are required by
specific pathogens to survive and replicate in the host cell [2]. In addition, in vitro tests on peripheral
blood cells from patients with different infectious disease phenotypes have led to the identification of
some genes involved in innate immune response as significantly associated with an increased risk of
severe disease [3]. This approach is, however, not feasible when the disease phenotype is restricted to
some tissues or cells, which are not accessible in vivo, such as the brain in viral encephalitis or the liver
in viral hepatitis.
The recent biotechnology breakthrough on cell reprogramming and generation of induced pluripotent
stem cells (iPSCs) [4], which has revolutionized the approaches to study the mechanisms of genetic and
degenerative diseases and to test new drugs, can be exploited to generate patient-specific models for the
investigation of host-pathogen interactions. Patient-specific iPSC-derived systems represent versatile,
non-invasive, ethically sustainable, and cruelty-free platforms to analyze the innate immune response to
pathogens and to test new therapies. Here we will review the applications of iPSCs to the study of viral
infections in humans that have been recently reported in the literature, which show the potentialities of
this new biotechnological platform. These studies include in vitro modeling of viral infections of neural,
liver, and cardiac cells; modeling of human genetic susceptibility to severe viral infectious diseases,
such as encephalitis and severe influenza; genetic engineering and genome editing of patient-specific
iPSC-derived cells to confer antiviral resistance, with applications for the development of therapies
against human immunodeficiency virus (HIV) and hepatitis virus infection.
2. Induced Pluripotent Stem Cell-Derived Models of Diseases
The advent of the reprogramming technology that allows generating patient-specific iPSCs from
differentiated somatic cells of the body has provided unprecedented human models to study both disease
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pathology in different genetic backgrounds and their response to therapy. Actually, human iPSCs have
been generated from a variety of somatic cells, e.g., fibroblasts, keratinocytes, peripheral blood cells,
and have been differentiated into almost any cell type of the body, including disease-relevant cell types,
like cardiomyocytes, hepatocytes, and neurons [5]. If derived from patients with a disease phenotype,
these cells will express the entire genetic background of the patient, including not only known gene
mutations, if present, but also all of the genetic modifiers that have important, yet unknown, roles in
disease pathogenesis [5].
2.1. Generation of iPSCs
The generation of iPSCs was first achieved in 2006 by Takahashi and Yamanaka [4], who
demonstrated that cells with embryonic stem cell features could be derived from mouse fibroblasts by
ectopic expression of four stem cell transcription factors (i.e., Oct4, Sox2, Klf4, and c-Myc). In the
following year, iPSCs were generated for the first time from human somatic skin cells by using similar
reprogramming protocols [6,7]. Like embryonic stem cells, human iPSCs can be grown indefinitely
and differentiated into a variety of cells, but without the use of embryos or somatic cell nuclear transfer
(Figure 1).
So far, different methods have been set up for the generation of iPSCs and efficient and standardized
reprogramming protocols are now available [8]. The first methods exploited integrating retroviral vectors
for the delivery of reprogramming factors, which, however, have been associated with the risk of
tumor development due to insertional mutagenesis and/or transgene reactivation. Efficient and safe
non-integrating methods based on the use of Sendai viral vectors, episome plasmid vectors, synthetic
mRNAs and small molecules have been subsequently developed and are now widely applied in stem
cell laboratories [8]. Particular attention is currently also given to the substrates used to generate human
iPSCs in order to obtain GMP-grade cells usable for clinical purposes. The majority of reprogramming
protocols are carried out, in fact, by using a layer of mitotically inactivated mouse embryonic fibroblasts
(MEFs), which pose the risk of xeno-factor contamination. The usage of MEFs may, in fact,
transfer exogenous antigens, unknown viruses, or zoonotic pathogens to iPSCs, contaminating the
culture, as it was already shown for immunogenic non-human sialic acid N-glycolylneuraminic acid
(Neu5Gc), detected on the surface of human embryonic stem cells maintained on MEF feeder [9]. This
contamination might represent a problem in the setup of infectious disease models and especially in the
development of iPSC-based therapies. In order to overcome this issue, many research groups have been
working on generating human iPSCs using human cells as feeder layers [10,11] or even, more recently,
using the same iPSCs lines to generate, by differentiation, fibroblast-like cells to be employed as feeder
layer [12]. Extracellular matrix- or synthetic-based substrates such as Matrigelr or vitronectin have also
been extensively studied to generate feeder-free human iPSCs. For these latter methods, however, the
reprogramming efficiencies are lower [13,14].
2.2. Features of iPSCs
The biological characteristics of human iPSCs are very similar to those of embryonic stem cells
(i.e., pluripotent cells derived from preimplantation stage embryos). Like embryonic stem cells, iPSCs
have unlimited self-renewal capacity and the potential to differentiate into all somatic cell types of the
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body. Different tests are used to define the pluripotent stem cell features of iPSCs, including analysis
of expression of stem cell marker genes (such as alkaline phosphatase, Nanog, Oct4), whole gene
expression profiling, promoter methylation analysis, and evaluation of the ability of iPSCs to differentiate
into cells of the three germ cell layers, i.e., ectoderm, mesoderm, and endoderm, by induction of
teratomes in vivo or by the Embryoid bodies (EBs) test in vitro.
Several protocols are available for the differentiation of iPSCs into a variety of cell types, including
neurons, cardiomyocytes, hepatocytes, keratinocytes, and hematopoietic cells [15]. There are three
general approaches to initiate differentiation: the first method is based on the fact that in vitro
differentiation recapitulates the stepwise stages of embryological development and exploits the formation
of EBs, i.e., 3D cellular aggregates obtained by withdrawal of undifferentiating stimuli such as adhesion
and b-FGF, and the subsequent spontaneous trigger of the differentiation pathway [16,17]. In the
second approach, pluripotent stem cells are grown directly on stromal cells, and differentiation takes
place in contact with these cells [18]. The third protocol starts with cells growing in a uniform
monolayer on extracellular matrix proteins [19,20]. All these different approaches offer advantages and
disadvantages, but share the delivery in cell growth medium of key factors that regulate the events of cell
differentiation during embryonic development. Since the resulting differentiated cells are heterogeneous
and may maintain immature characteristics, selection of specific cell subtypes by cell sorting and
antibiotic selection is needed for applications in disease modeling and regenerative medicine. For these
applications, cells can be grown in co-cultures and in three-dimensional scaffolds [21] to generate tissues,
such as liver [22], cardiac tissue [23], and neural tissue [24].
2.3. Disease Modeling Using Human iPSCs
Human iPSCs have been applied to the modeling of a variety of human diseases [25,26]. Most
applications regarded pathogenesis studies, drug testing, and drug discovery for genetic and degenerative
diseases, and, among these, mainly cardiovascular and neurological diseases [5], while applications in
infectious diseases have been very limited (Figure 1). For example, several studies used patient-specific
iPSC-derived cardiomyocytes to model long QT syndrome and other arrhythmia syndromes and used
the cells to rescue the disease phenotype and as platform for drug testing in vitro [27–30]. Likewise,
in vitro models of monogenic and multi-factorial neurological and metabolic diseases have been set up
using patient-specific iPSC-derived cells [31–37].
The development of in vitro models of human diseases based on patient-specific iPSC-derived cells
requires standardized and reproducible methods of reprogramming and cell differentiation, in order to
minimize technical variability and biases. In addition, the setup of robust and simple assays for the
detection of specific disease traits is required to analyze the disease phenotype in patient-derived cells
(e.g., measurement of amyloid-β and phospho-tau in neural cell lysates as a marker of Alzheimer’s
disease [35]; electrophysiology measurements to analyze alterations in ion channels [27]). These
assays should be suitable for scaling up, especially if the iPSC-derived cell platforms are used for
high-throughput drug screening or toxicity studies. To this aim, automated cell cultures and lab-on-chip
platforms may be used for high throughput analyses [38,39], including the modeling of viral infections
in vitro [40,41]. Adequate controls are also required to distinguish disease-specific phenotypes from
inter-individual variability or technical variability related to iPSCs generation. Controls for monogenic
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disease models may be obtained by rescuing the mutated gene in iPSCs by targeted gene correction.
Gene correction can now be efficiently achieved through homologous recombination using zinc-finger
nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), or CRISPR/Cas9 nucleases,
i.e., a gene editing system composed of clustered regularly interspaced short palindromic repeats
(CRISPRs) together with CRISPR-associated nuclease (Cas) [42]. These techniques can also be used to
introduce specific mutations in iPSCs to generate disease-specific genotypes. However, these approaches
are quite labor intensive and can be applied only to diseases associated with known mutations. As an
alternative, well-characterized iPSCs derived from matched healthy individuals can be used as controls.
mutations in iPSCs to generate disease-specific genotypes. However, these approaches are quite labor 
intensive and can be applied only to diseases associated with known mutations. As an alternative, well-
characterized iPSCs derived from matched healthy individuals can be used as controls. 
 
Figure 1. Representation of the workflow for the derivation of patient-specific induced 
pluripotent stem cells, their differentiation in somatic cells and tissues, and their use for 
disease modeling, drug screening, and development of personalized therapies. 
3. Use of Human iPSCs to Model Viral Infections 
The use of human iPSCs is particularly helpful to set up in vitro cultures of normal human cells for 
viruses that are strictly species-specific or that can grow only in a limited set of human cell types,  
like herpes simplex virus (HSV) and varicella zoster virus (VZV), which have tropism for neural cells 
and establish latency in sensory neurons; human cytomegalovirus (HCMV), which can be isolated and 
propagated in human endothelial cells; hepatitis B (HBV) and hepatitis C (HCV) viruses, which can be 
grown in hepatocytes. The availability of human iPSC-derived differentiated cells allows setting up 
potentially unlimited and easy to handle cell systems for the investigation of viral tropism, pathogenesis, 
latency, reactivation, and interaction with the human host. Applications of human iPSCs to model viral 
infections and relevant findings reported in the literature are summarized in Table 1. 
3.1. Human Cytomegalovirus Infection 
Human cytomegalovirus is a betaherpesvirus that has tropism for vascular endothelial cells, blood 
monocytes, and neural cells [43]. Cellular determinants that regulate HCMV replication within these  
cell lineages are dictated largely by the stages of cell differentiation. Infection of monocytes and their 
progenitors favors latent HCMV infection [44,45], while differentiation of monocytes into tissue 
macrophages promotes viral replication [46]. Replication in endothelial cells is important for HCMV 
hematogenous dissemination during acute infection and for vertical transmission from mother to  
fetus [47–50]. Endothelial cells have also been suggested to be sites of viral persistence during latency [47]. 
HCMV can also infect the central nervous system (CNS) and is the most common cause of congenital 
CNS infection [51]. 
Clinical isolates of HCMV display variable tropism in vitro and this variability may be associated 
with virulence traits. Actually, laboratory adapted HCMV strains are typically grown in fibroblasts and 
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disease modeling, drug screening, and development of personalized therapies.
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The use of hu an iPSCs is particularly helpful to set up in vitro cultures of normal human cells
for viruses that are strictly species-specific or that can grow only in a limited set of human cell types,
like herpes simplex virus (HSV) and varicella zoster virus (VZV), which have tropism for neural cells
and establish latency in sensory neurons; hu an cyto egalovirus (HC V), which can be isolated and
propagated in a e t elial cells; hepatitis B (HBV) and hepatitis C (HCV) viruses, which can
be grown in hepatocytes. The availability of human iPSC-derived differe tiat lls ll s setting up
potentially unlimited and easy to handle cell syste s for the investigation of viral tropism, pathogenesis,
latency, reactivation, and interaction with the human host. Applications of human iPSCs to odel viral
infections and relevant findings reported in the literature are summarized in Table 1.
3.1. u an yto egalovirus Infection
Human cytomegalovirus is a betaherpesvirus that has tropism for vascular endothelial cells, blood
monocytes, and neural cells [43]. Cellular determinants that regulate HCMV replication within
these cell lineages are dictated largely by the stages of cell differentiation. Infection of monocytes
and their progenitors favors latent HCMV infection [44,45], while differentiation of monocytes into
tissue macrophages promotes viral replication [46]. Replication in endothelial cells is important for
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HCMV hematogenous dissemination during acute infection and for vertical transmission from mother
to fetus [47–50]. Endothelial cells have also been suggested to be sites of viral persistence during
latency [47]. HCMV can also infect the central nervous system (CNS) and is the most common cause of
congenital CNS infection [51].
Clinical isolates of HCMV display variable tropism in vitro and this variability may be associated with
virulence traits. Actually, laboratory adapted HCMV strains are typically grown in fibroblasts and this
adaptation is associated with genetic mutations and loss of natural tropism features [48,52,53]. Limited
access to normal human cells and tissues and technical difficulties in sustaining primary human cell
cultures have represented an obstacle to the investigation of the mechanisms of HCMV pathogenesis
and host antiviral response. To overcome these problems, human embryonic stem cells and, more
recently, iPSCs have been applied to generate human neural cells and tissues and used as models to
investigate HCMV infection of human neural fetal brain and cellular response in vitro [54–56]. These
studies, which showed that the in vitro models may represent valuable surrogates of in vivo infection
experiments [54], demonstrated that primitive neural stem cells (NSCs), similar to those present in the
developing neural tube, did not support HCMV replication but instead allowed persistent infection, while
lytic infection was induced upon differentiation of progenitor NSCs into neurons [55]. These results are
in contrast to the results obtained in human iPSC-derived NSCs, neural progenitor cells (NPCs) and
neurons, which showed that both iPSCs and iPSC-derived neurons were not permissive, while NPCs
were fully permissive for HCMV replication [56].
3.2. Herpes Simplex Virus and Varicella Zoster Virus Infection of Neural Cells
HSV and VZV are human neurotropic alphaherpesviruses with strict tropism for the human host.
Following primary infection, both viruses establish latency in sensory neurons of the dorsal root and
trigeminal ganglia. Human iPSCs have been differentiated into NPCs and sensory neurons and used to
model HSV and VZV infection and disease [57,58]. In vitro experiments showed that iPSCs supported
HSV but not VZV infection, while NPCs and differentiated cell cultures containing sensory neurons
could be productively infected by both viruses, which caused a significant cytopathic effect (CPE) [57].
3.3. Hepatitis B Virus Infection
HBV is a small DNA virus of the Hepadnaviridae family that selectively infects hepatocytes in the
human liver. Approximately 400 million people worldwide have chronic HBV infection, of whom
about one-third will develop end-stage liver disease and liver cancer [59]. Research on HBV biology
and antiviral therapy has been hampered by the lack of suitable liver models of HBV infection that
recapitulate HBV life cycle and its interaction with the host. Different models of HBV infection have
been developed.
Human primary adult hepatocyte cultures, which are considered the gold standard, can support HBV
replication in vitro, but these cells are difficult to maintain [60]. Co-culture of primary hepatocytes
with supportive stromal cells has allowed prolonging hepatocyte viability and their differentiated
phenotype [61,62].
More recently, with the identification of the bile acid pump sodium taurocholate cotrasporting
polypeptide (NTCP) as a receptor for both HBV and hepatitis D virus [63], infection models have been
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set up by ectopic expression of NTCP in hepatocellular carcinoma cells [64] and in transgenic mice [65].
However, hepatocellular carcinoma cells have altered innate immune response and cell proliferation
mechanisms, thus limiting the usefulness of this model to the study of HBV infection.
Human iPSCs have been also exploited to generate a model of HBV infection [62]. In particular,
human iPSCs have been differentiated into hepatocyte-like cells and grown in co-cultures with stromal
fibroblasts. Infection of cells with HBV showed that fully differentiated hepatocyte-like cells, but
not cells at earlier stages of differentiation, supported productive infection. Treatment of cells with a
broad-spectrum Janus kinase inhibitor to block the induction of interferon-stimulated genes allowed to
maintain HBV replication over a period of three weeks, while treatment with interferon or with the
antiviral drug entecavir decreased viral titer [62]. These data indicate that this platform can be used to
test anti-HBV drugs, besides modeling virus–host interactions.
3.4. Hepatitis C Virus Infection
HCV infection is an important cause of liver cirrhosis and hepatocellular carcinoma worldwide [66].
Research on HCV infection has been hampered by the lack of relevant in vitro and in vivo models.
The most used cell culture model of HCV infection is based on the human hepatocellular carcinoma
cell line Huh7 and the JFH1 replicon of HCV of genotype 2a [67]. Huh7 cells transfected with the
replicon produce infectious progeny viruses and recapitulate the entire viral life cycle [68–71]. The virus
produced by this system can be used to infect primary human hepatocytes, which are the natural targets
for HCV and are permissive to infection both in vitro [72–74] and in vivo after engraftment [75,76].
Primary human hepatocytes are obtained from patient biopsies and represent a physiological model of
HCV infection. They can be infected with cell culture-derived HCV JFH1 but also with HCV-positive
sera. However, their use is hampered by their limited availability, variable quality, high cost, and
short-term use.
In this context, hepatocyte-like cells derived from human iPSCs could represent a valuable
alternative to primary hepatocytes to model HCV infection in vitro [77,78]. In vitro differentiated
human hepatocytes and hepatic progenitor cells can be persistently infected with HCV and secrete
infectious viral particles into the culture medium, while iPSCs are not permissive for HCV
infection. Permissiveness to infection correlated with induction of the liver-specific microRNA-122
and modulation of cellular factors that affect HCV replication, such as epidermal growth factor receptor
(EGFR), ephrin receptor A2 (EphA2), and phosphatidylinositol 4-kinase type III alpha (PI4KIIIa) [77].
Human liver-like cells derived from patient-specific iPSCs have been also used to generate an in vivo
model, by their engraftment into the liver of transgenic mice [79–81]. These cells underwent further
maturation in vivo and could be persistently infected by HCV for more than three months [80].
A HCV replicon system in human iPSC-derived hepatocyte-like cells has been used as an in vitro
platform to investigate the hepatotoxicity of new combinations of drugs against HCV [82]. By using
patient-specific iPSC-derived cells, this system could be applied to the analysis of drug toxicity for
individual patients.
3.5. Enterovirus Myocarditis
Group B coxsackieviruses (RNA viruses belonging to the Enterovirus genus) are common causes
of viral myocarditis [83]. These viruses enter cardiomyocytes via the coxsackievirus and adenovirus
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receptor (CAR), a transmembrane cell adhesion protein, which is highly expressed in cardiomyocytes,
and efficiently replicate and induce necrosis in infected cells [84].
Human iPSC-derived cardiomyocytes have been used to model myocarditis induced by
coxsackievirus infection [85]. These studies have shown that cardiomyocytes derived from human
iPSCs express high levels of CAR and are susceptible to coxsackievirus infection. Human iPSC-derived
cardiomyocytes were also infected with an engineered coxsackievirus B3 strain expressing a luciferase
reporter gene and used as a platform to measure viral replication. This model allowed testing the efficacy
of antiviral drugs in reducing coxsackievirus replication in human cardiomyocytes [85].
Table 1. Human induced pluripotent stem cell (iPSC)-derived models of viral infections.
Disease
Model
Virus iPSC-Derived Cells Findings Refs
Encephalitis HCMV
Neural stem cells, neural
progenitor cells, neurons
Neural progenitor cells, but not
neurons, are permissive for lytic
HCMV replication
[56]
Encephalitis HCMV
Neural stem cells, neural
progenitor cells, neurons
Neural stem cells allow persistent
HCMV infection; neurons are
permissive for lytic replication
[55]
Encephalitis
HSV,
VZV
Neural progenitor cells,
sensory neurons
Neural progenitor cells and sensory
neurons are permissive to productive
HSV and VZV infection
[57]
Hepatitis HBV
Hepatic progenitor cells,
differentiated
hepatocytes
Fully differentiated hepatocyte-like
cells support productive HBV
infection
[62]
Hepatitis HCV
Hepatic progenitor cells,
differentiated
hepatocytes
Hepatic progenitor cells and
differentiated hepatocytes are
permissive for HCV infection
[77,78]
Hepatitis HCV
Hepatic progenitor cells,
differentiated
hepatocytes
Liver-like cells can be engrafted in
the liver of transgenic mice and
persistently infected by HCV
[79–81]
Myocarditis Coxsackievirus Cardiomyocytes
Cardiomyocytes are susceptible to
coxsackievirus infection
[85]
4. Modeling Human Susceptibility to Viral Infectious Diseases Using iPSC-derived Systems
Genome wide association studies and studies of monogenic diseases have identified some
polymorphisms and mutations in genes involved in innate and adaptive antiviral-immunity or encoding
viral receptors as associated with increased susceptibility or resistance to specific infectious disease
phenotypes and with response to antiviral therapy [2,86]. For example, mutations of the C-C chemokine
receptor type 5 gene (CCR5) confer resistance to HIV-1 infection, mutations of the Toll-like receptor 3
(TLR3) and UNC93B1 genes are associated with susceptibility to HSV-1 encephalitis, a polymorphism
upstream of interleukin 28B (IL28B) is associated with HCV spontaneous clearance and response to
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treatment with IFN-α [2]. Based on the clinical observation of the high variability of infectious disease
phenotypes in different individuals, it is conceivable that host genetic background plays an important
role in the outcome of many infections and that the spectrum of genetic polymorphisms and mutations
associated with viral disease phenotypes is larger than currently known. Patient-specific iPSCs can be
used to derive relevant cell types to model viral infectious disease phenotypes and virus-host interactions,
in order to get clues on the genetic basis and the mechanisms of individual susceptibility (or resistance)
to severe disease. Applications of iPSCs to model genetic susceptibility to viral infectious diseases have
been reported so far for HSV encephalitis and severe influenza, as described below and summarized in
Table 2.
4.1. Herpes Simplex Virus Encephalitis
Investigation of children with genetic predisposition to develop HSV-1 encephalitis was one of the
first applications of iPSCs to the study of patient-specific susceptibility to infectious diseases. Childhood
herpes simplex encephalitis is a rare, life threatening condition that predisposes otherwise healthy
children to encephalitis during primary HSV-1 infection. This syndrome has been associated with
mutations in the TLR3 gene, a key factor for natural immunity to HSV-1 in the CNS, or with mutations
in genes encoding factors involved in TLR3 response, such as UNC93B1 [87–90].
By using the iPSC technology, NSCs, neurons, astrocytes, and oligodendrocytes were derived from
TLR3- and UNC-93B-deficient patients and from control subjects and tested in vitro [91]. Experiments
showed that neurons and oligodendrocytes from TLR3- and UNC-93B-deficient patients had an impaired
IFN-β and IFN-λ1 response to the dsRNA analogue polyinosinic:polycytidylic acid (poly(I:C)) and to
HSV-1. In addition, neurons and oligodendrocytes from UNC-93B-deficient patients and neurons from
TLR3-deficient patients were much more susceptible to HSV-1 infection than control cells [91]. Impaired
interferon response and HSV-1 susceptibility phenotype could be rescued by transient expression of the
corresponding wild-type allele and by treatment with exogenous IFN-α or IFN-β but not IFN-λ1, thus
indicating that impaired IFN-α/β intrinsic immunity to HSV-1 in the CNS may underlie the disease
pathogenesis [91].
4.2. Severe Influenza
Influenza virus infection typically causes a self-limiting respiratory disease, but can occasionally
cause life-threatening acute respiratory distress syndrome (ARDS). The presence of co-morbidities is
a risk factor for ARDS, but in some cases this condition may occur in otherwise healthy individuals.
A recent study demonstrated that severe influenza may result from a single-gene inborn error of
immunity [92]. In this study, two compound heterozygous mutations in the transcription factor interferon
regulatory factor 7 (IRF7) gene were identified by whole-exome sequencing in an otherwise healthy
seven year-old girl who suffered life-threatening ARDS during primary infection with pandemic H1N1
2009 influenza virus. Interferon regulatory factor 7 is a transcription factor that amplifies type I and
type III interferon responses to viral infection. In vitro functional assays demonstrated that the two
mutations caused loss-of-function of IRF7. Patient’s peripheral blood mononuclear cells (PBMCs) and
plasmacytoid dendritic cells infected with influenza A virus showed a significant down-regulation of type
I and type III interferon genes in comparison with healthy donors and deficient IFN-α2 production after
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infection with 11 different viruses or stimulation with TLR agonists. To model the impact of the IRF7
mutations on patient’s respiratory tract, pulmonary epithelial cells were generated from patient’s iPSCs.
These cells produced reduced amounts of type I IFN and displayed increased influenza virus replication
in comparison with control cells. Treatment with IFN-α2b, IFN-β, or IFN-λ1 rescued this phenotype.
These findings suggested that impairment of IRF7-dependent amplification of IFN response in dendritic
cells and in the pulmonary epithelium may have contributed to patient’s ARDS [92].
Table 2. Human induced pluripotent stem cell (iPSC)-derived models of genetic
susceptibility to viral infectious diseases.
Disease Genetic Defect
Disease Traits in
Patients
Phenotype in Human
iPSC-Derived Cells
Rescue and
Drug Testing
Refs
HSV
encephalitis
Inactivating
mutations of
TLR3 and
UNC93B1
Predisposition to
develop encephalitis
during primary HSV-1
infection
Impaired IFN response to
HSV infection and
increased HSV replication
in patient-specific neurons
and oligodendrocytes
Gene addition;
interferon
[91]
Severe
influenza
Inactivating
mutations of
IRF7
Development of acute
respiratory distress
syndrome during
influenza virus
infection
Impaired IFN response
and increased influenza
virus replication in
patient-specific pulmonary
epithelial cells
Interferon [92]
5. Human iPSC-Based Antiviral Strategies
Genetic engineering and gene editing technologies may be used to confer antiviral resistance to
patient-specific cells. This result can be achieved by knocking out viral receptor genes or host co-factors
that are critical for viral replication, by enhancing cell-based immunotherapy, or by targeting the viral
genome. Proof-of-concept studies of these new antiviral strategies have been reported for HIV-1, HBV,
and HCV, as described below and summarized in Table 3.
5.1. Human Immunodeficiency Virus
Human immunodeficiency virus infects immune cells and integrates into the host genome to establish
its latent infection. This represents a major challenge to the development of efficient therapies and
vaccines capable to cure or prevent HIV infection.
By exploiting iPSC technology in combination with gene silencing or gene editing methods, new
therapeutic strategies aiming at conferring resistance to HIV in patient-specific cells have been proposed.
These strategies included the use of short hairpin RNA (shRNA) or engineered nucleases, i.e., ZFNs,
TALENs, or the CRISPR/Cas9 system, to disrupt viral RNA or latently integrated viral genome; to
engineer iPSC-derived NK cells to enhance killing of HIV-infected cells; to down-regulate or inactivate
CCR5, the main co-receptor for HIV.
While the delivery of shRNAs generally can only produce a partial and transient inhibition of targeted
RNA expression, the use of engineered nucleases allows to completely knocking down target sequenced
by editing the cellular genome.
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A highly effective engineered nuclease-based gene editing system exploits CRISPR/Cas, which has
evolved in bacteria and archaea as an antiviral defense system. The antiviral activity of this system
is based on the recognition of specific sequences in the target viral genome and their cleavage with
the generation of site-specific DNA double-stranded breaks (DSBs) [93]. One of these systems,
the type II CRISPR/Cas9 system from Streptococcus pyogenes [94] has been adapted to mammalian
cells to generate site-specific insertions/deletions by introducing DSBs followed by non-homologous
end-joining repair or to generate genome editing by introducing DSBs followed by homologous direct
repair [95,96]. Likewise, the nucleases ZFNs and TALENs can be engineered and targeted to host
genome for gene editing through non-homologous end-joining repair or homologous direct repair [97].
In the first anti-HIV approach that exploits iPSCs, gene-editing tools were used to excide the
integrated HIV-1 provirus from the host cell genome [98–100] and to directly target and disrupt the
reverse-transcribed HIV genome within host cells [101]. In particular, the study by Liao et al. [101]
demonstrated that transient transfection of the CRISPR/Cas9 system in cells transduced with a lentivirus
carrying an EGFP reporter led to targeted disruption of both pre-integration viral genomes and integrated
proviruses. Improved HIV disruption was achieved by targeting the LTR regions or by targeting multiple
viral genome sites. The HIV-targeted CRISPR/Cas9 system was effective also in latently infected T-cell
lines and in iPSC-derived monocytes/macrophages (i.e., the cellular reservoirs for HIV), providing
long-term resistance to HIV-1 challenge [101].
The second approach aimed to generate natural killer (NK) cells and to enhance their antiviral
activity. To this aim, human embryonic stem cells and iPSCs were used as a source of NK cells and the
ability of these cells to suppress HIV-1 infection was shown to utilize different mechanisms, including
direct lysis of target cells, antibody-dependent cellular cytotoxicity, and production of chemokines and
cytokines [102]. To enhance the antiviral activity, iPSC-derived NK cells were engineered to express a
HIV chimeric receptor, combining the extracellular portion of CD4 to the CD3ζ intracellular signaling
chain, and used to generate NK cells. In vitro and in vivo experiments using a humanized mouse model
demonstrated that the engineered NK cells inhibited HIV replication in CD4+ T-cells more efficiently
than their unmodified counterparts [103].
The third therapeutic strategy was based on the down-regulation or genetic modification of the
CCR5 co-receptor for HIV. A proof of concept of this approach was demonstrated by co-transducing
fibroblasts with a vector carrying CCR5 shRNA in addition to the reprogramming vectors to generate
iPSCs [104]. Improved differentiation of iPSCs into hematopoietic cells for a potential therapeutic use
can be achieved by using iPSCs derived from hematopoietic stem cells or human epithelial cells. In
this regard, cord blood CD34+ cells have been used to generate anti-HIV iPSCs, which carried CCR5
shRNA in combination with a chimeric human/rhesus TRIM5αmolecule [105], which was demonstrated
to be a potent pre-integration inhibitor of HIV-1 infection [106]. These cells could be continually
grown and differentiated into colony-forming hematopoietic progenitors, which subsequently developed
into phenotypically and functionally normal macrophages resistant to HIV-1 infection [105]. Gene
editing of CCR5 was achieved by introducing in target cells the naturally occurring 32-bp homozygous
deletion in CCR5 (CCR5∆32), which confers resistance to HIV-1 infection. By using a combination
of TALENs, CRISPR/Cas9, and the piggyBac technology, this mutation was introduced into iPSCs
with high efficiency. The modified iPSCs were then differentiated into monocytes/macrophages, which
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demonstrated their resistance to HIV-1 challenge [107]. Other cellular genes involved in the control of
HIV infection, transcription, and replication could be also targeted as an antiviral strategy, such as in
the case of knockdown of cyclin-dependent kinase (CDK2) expression in iPSC-derived macrophages by
shRNA to inhibit HIV-1 transcription [108].
5.2. Hepatitis Viruses
Gene editing of target cells to confer viral resistance has been applied also to generate hepatocytes
resistant to HCV [77]. Transplantation of hepatocytes resistant to HCV could be used as a potential
life-saving therapy in HCV-positive liver transplant recipients, who experience a high risk of reinfection.
To provide a proof-of-concept of the possibility to generate HCV-resistant differentiated human
hepatocytes, cells at the pluripotency stage were transduced with lentiviral vectors carrying shRNAs
directed at cyclophilin A and PI4KIIIa, which are important cofactors for HCV replication [109]. These
cells were then differentiated into hepatocytes and infected with wild type HCV. In these cells, levels of
viral replication were undetectable, like in mock infected control cells. This is an interesting therapeutic
approach for an RNA virus characterized by high mutation and turnover rates, for which inhibiting a
cellular rather than a viral target may offer the advantage of a higher genetic barrier to development
of resistance.
For HBV therapy, gene editing was targeted to the viral genome. In particular, the CRISPR/Cas9
system was used to target the surface antigen (HBsAg)-encoding region of HBV and tested in
human hepatoma cell lines and transgenic mice carrying the HBV genome and expressing HBsAg in
serum [110]. A significant reduction of HBsAg levels was observed in cell culture supernatant in vitro
and in mouse serum in vivo, HBsAg-positive cells were eliminated in liver tissue, and mutations in HBV
genome were demonstrated [110]. In this study, no iPSC-derived systems were used. However, besides
its in vivo use, this therapeutic strategy could be easily applied to generate ex vivo patient-specific cells
resistant to HBV infection.
6. Conclusions
In this review article, we presented and discussed applications of the iPSC technology to develop
in vitro models of human viral infections. Although the studies reported in the literature are very few
in comparison with the numerous applications for other inherited and degenerative diseases, the results
achieved in virology are remarkable and suggest that iPSC technology could be very useful for many
other applications in the modeling of virus—human cell interactions, in the study of patient-specific
viral disease outcome and response to antiviral therapies, and as platforms for the development of new
antiviral strategies.
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Table 3. Patients-specific induced pluripotent stem cell (iPSC)-based antiviral strategies.
Virus Antiviral Strategy
iPSC-Derived
Target Cells
Results Refs
HIV
Disruption of
integrated HIV
genome
T cells,
monocytes/
macrophages
HIV-targeted CRISPR/Cas9 disrupts
reverse-transcribed and integrated HIV
genome
[101]
HIV
Enhanced immune
response
NK cells
Antiviral activity of iPSC-derived NKs;
engineering a HIV chimeric CD4/CD3ζ
receptor enhances NK activity against HIV
[102,103]
HIV
Viral receptor
inactivation
Monocytes/
macrophages
Knockdown of CCR5 by shRNA;
introduction of the CCR5∆32 mutation by
genome editing confers resistance to
HIV-1 infection
[104,105,107]
HIV
Downregulation of
viral cofactors by
shRNAs
Monocytes/
macrophages
Inhibition of CDK2 and TRIM5α inhibits
HIV-1 transcription
[105,108]
HCV
Downregulation of
viral cofactors by
siRNAs
Differentiated
hepatocytes
Inhibition of cyclophilin A and PIaKIIIa
inhibits HCV replication in hepatocytes
[109]
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